The kidney is important not only as a target organ of hypertension but also as a organ that may cause hypertension. For many years, we have studied basic and clinical aspects of the role of the kidney in hypertension, including the renin-angiotensin, kallikrein-kinin, and prostaglandin systems, glomerular hemodynamics, therapeutic modalities, and prognosis. This review summarizes some of our results together with those of other relevant studies in the literature. (Hypertens Res 1997; 20: 75-84) 
The kidney plays an important role in the control of systemic blood pressure by regulating the composition of body fluid and electrolytes and by producing and releasing various vasoactive substances, such as renin-angiotensin, kallikrein-kinin, and prostaglandins (PGs) . In various renal diseases, systemic blood pressure is known to become higher as renal function deteriorates, while systemic hypertension further aggravates renal dysfunction. Furuyama et al. (1) found a positive correlation between the index of glomerular lesions (IGL) and mean blood pressure in patients with biopsy-proven mesangial proliferative glomerulonephritis. In addition, in studies following up 366 patients with mesangial proliferative glomerulonephritis or membranoproliferative glomerulonephritis for more than 10 yr, Saito et al. (2) observed that among patients with similar IGL values, the presence of systemic hypertension was associated with a significantly decreased renal survival rate. Thus, hypertension is obviously a risk factor for progression of renal dysfunction. In another study, we followed up for 30 yr 2,164 patients who visited our clinic between 1956 and 1964 and were thoroughly evaluated and given a diagnosis of essential hypertension (3) . We found that about 50% of the patients with a glomerular filtration rate (GFR) of less than 50 mi/min died within a couple of years, demonstrating a poor outcome in essential hypertensive patients once hypertensive renal damage develops. The poor outcome in those days can be attributed to the lack of effective antihypertensive drugs, such as calcium antagonists or angiotensin converting enzyme inhibitors (ACEi).
Hypertension and Renal Hemodynamics
Renal cross-transplantation studies have provided clear evidence for a pivotal role of the kidney in the pathogenesis of hypertension (4) . Many investigators have demonstrated that when genetically hypertensive animals are nephrectomized bilaterally and receive a kidney transplant from normotensive control animals, they become normotensive. Conversely, when normotensive animals receive a kidney from hypertensive animals, they become hypertensive. In a clinical study, hypertension in patients with chronic renal failure caused by essential hypertension was cured after they received kidney transplants from normotensive donors without a family history of hypertension (5) . These studies suggest that the kidney plays a critical role in the pathogenesis of systemic hypertension.
The kidney possesses an intrinsic mechanism called "pressure-natriuresis,"
in which an increase in perfusion pressure (systemic blood pressure) promotes natriuresis (6) . This would lead to the assumption that persons with a high NaCI intake should have a higher systemic blood pressure in order to achieve a steady state. In normal subjects, however, dietary sodium intake has little effect on systemic blood pressure, rendering the slope of the pressurenatriuresis curve very steep (Fig. 1) . The pressurenatriuresis curve indicates that hypertensive subjects can be classified as salt-sensitive or non-salt-sensitive based on their responses to dietary sodium loading. Thus, a shift of the curve to the right and a decrease in the slope are the two basic abnormalities seen in the pressure-natriuresis relationship in hypertension, with each representing a different pathophysiology, particularly in terms of renal hemodynamics. In essential hypertension without organ damage (non-salt-sensitive type), renal blood flow and the GFR remain within a normal range despite a high systemic blood pressure, indicating an elevated renal vascular resistance. Micropuncture studies in the spontaneously hypertensive rat (SHR) and its normotensive control, the Wister Kyoto (WKY) rat, have demonstrated that glomerular capillary pressure is the same despite a higher systemic blood pressure in SHR (7) . Thus, the increased vascular resistance is localized only to the preglomerular vasculature. Calculation of glomerular capillary pressure according to Gomez's equation suggests that in human essential hypertension glomerular capillary pressure is also within the normal range, with increased preglomerular resistance (8) . Among various preglomerular vascular segments, the afferent arteriole is likely to be the major contributor to the elevated vascular resistance.
The issue of whether increased afferent arteriolar resistance can cause hypertension remains unanswered. Using the F2 generation of cross-bred SHR and WKY, Norrelund et al. (9) examined the relationship between the afferent arteriolar diameter of one kidney removed at the age of 7 wk and systemic blood pressure measured at the age of 23 wk in the same animals. They found that the smaller the diameter at 7 wk, the higher was the blood pressure at 23 wk. These data suggest that constriction of afferent arterioles may be involved in (or at least be a predictor of) the later development of systemic hypertension. Thus, increased afferent arteriolar resistance seems to play a central role in the pathophysiology of essential hypertension, which is also reflected in the histologic characteristics of benign nephrosclerosis, namely, the thickening and sclerosis of interlobular and afferent arterioles with relatively spared glomeruli.
On the other hand, salt-sensitive hypertension is characterized by the inability of the kidney to excrete unnecessary amounts of sodium loaded into the body. This may be caused by either a decreased ultrafiltration coefficient or increased tubular reabsorption. When dietary sodium intake is increased under such abnormalities, body fluid volume, and hence systemic blood pressure, increase, leading to an elevated glomerular capillary pressure and therefore an increase in the GFR. With such increases in GFR, more sodium is loaded to the tubules to maintain sodium balance. Thus, in salt-sensitive hypertension, glomerular hypertension is a common feature regardless of the cause of hypertension, such as diabetic nephropathy, primary aldosteronism, chronic glomerulonephritis, and essential hypertension seen in black populations (10) . Since glomerular hypertension contributes significantly to glomerular damage (11) , renal function declines more rapidly in salt-sensitive types of hypertension than in essential hypertension (non-salt-sensitive) in which glomerular capillary pressure is normal. Taken together, available evidence indicates that glomerular hemodynamics may be important not only for the genesis of hypertension but also for the mode of progression of renal dysfunction.
The renal structure that controls glomerular hemodynamics is the juxtaglomerular apparatus (JGA), which displays a unique arrangement of the glomerular afferent and efferent arterioles, a plaque of specialized tubular epithelial cells called the macula densa, and extraglomerular mesangial cells. The JGA has long been known as the site regulating renin synthesis and release (12) . In addition, studies have demonstrated that the JGA possesses two intrinsic mechanisms that directly control glomerular hemodynamics independently of the reninangiotensin system. They are the myogenic response and the macula densa-mediated tubuloglomerular feedback (TGF), both of which are important to autoregulation of renal blood flow and the GFR. In order to study these two mechanisms directly, we developed in vitro preparations in which microdissected afferent arterioles are perfused either alone or together with the attached macula densa ( Fig. 2 ) (13) (14) (15) (16) (17) . We found that afferent arterioles constricted significantly when either intraluminal pressure of the afferent arteriole or NaCI concentration at the macula densa was elevated (Fig. 3) , demonstrating the myogenic response and the TGF, respectively. Of note is the fact that the myogenic response and the TGF exist in series along the afferent arteriole, with the former being in the more proximal and the latter in the terminal segment. Thus, the myogenic response is the first to respond to changes in renal perfusion pressure in order to maintain glomerular capillary pressure constant, while any changes in GFR that are not prevented by the myogenic response are reflected as changes in NaCI concentration at the macula densa, with subsequent tuning of the distal segment by the TGF. Such interactions of the myogenic response and TGF enable the kidney to achieve the most efficient autoregulation as compared with any other organ in the body. Indeed, when the distal C1 concentration and the proximal tubular pressure, an index of single nephron GFR, were measured stimaltenously, they were found to oscillate synchronously, with an increase in the C1 concentration being associated with a decrease in the pressure (18) . These studies indicate that the TGF is an exquistley intricate mechanism for maintaining a constant GFR at the single nephron level.
The myogenic response and TGF are found to be altered in various forms of hypertension. The myogenic response is attenuated in Dahl salt-sensitive hypertensive rats (19) and in diabetic rats (20) , permitting transmission of systemic blood pressure to the glomerulus and thereby causing glomerular hypertension. On the other hand, Hayashi et al. (21) and Ito et al. (16) reported that the myogenic response is exaggerated in SHR. The TGF has also been shown to be exaggerated in SHR and Milan hypertensive rats (22) (23) (24) , so that at similar NaCI concentrations at the macula densa, the single nephron GFR decreases because of stronger constriction of the afferent arteriole, as compared with their normotensive controls. Together with the exaggerated myogenic response, such alterations in the TGF may contribute to the elevated preglomerular vascular resistance seen in SHR.
Renin-Angiotensin System
It is well established that ACEi and angiotensin type I receptor antagonist are both effective in reducing blood pressure in essential hypertension. In addition, recent studies have shown that overexpression of the renin gene results in hypertension (25) , whereas hypotension is usually observed when the gene encoding components of the reninangiotensin system is disrupted (26, 27) . These studies unequivocally demonstrate that the reninangiotensin system has an important part in the control of systemic blood pressure.
Renin is synthesized and released by the granular juxtaglomerular cells (JO cells), which are present mainly in the media of the distal afferent arteriole. There are four mechanisms operating at the JGA to control renin release (12) . They are 1) the baroreceptor mechanism, in which the JG cells respond to changes in perfusion pressure, with increased pressure decreasing renin release; 2) the macula densa mechanism, in which increases in Cl-concentration of the tubular fluid at the macula densa cause decreased renin release and vice versa; 3) the sympathetic nervous system involving /3-receptors; and 4) various systemic and local hormones. In order to assess the role of the renin-angiotensin system in the regulation of blood pressure, we measured plasma renin activity (PRA) in 160 patients with essential hypertension and found wide variations not only in basal PRA but also in renin responses to furosemide plus 2-h upright posture (28) . In addition, both PRA and plasma renin concentration were found to decrease with aging (29) . Moreover, we have demonstrated that increases in PRA induced by either dietary sodium depletion plus furosemide or the ACEi captopril were attenu- ated by oral administration of indomethacin (30, 31) , suggesting an important role of PGs in the renin responses. Finally, in studies measuring PGE2 and its metabotes in the urine, we observed that furosemide significantly increased urinary PGE2 excretion but drastically decreased excretion of its metabolites (Fig. 4) (32) . Thus, we proposed that furosemide inhibits breakdown of PGE2, leading to its accumulation within the kidney, which may account, at least in part, for furosemide-induced natriuresis and increases in renin release.
More recently, we have developed a unique preparation of microdissected afferent arterioles with or without attached macula densa for the study of renin release (33) . We found that the basal rate of renin release was lower in the afferent arterioles with the attached macula densa than those without, perhaps due to a high NaCI concentration of our incubation medium (and hence, at the macula densa) as compared with that of the tubular fluid at the macula densa in vivo. In addition, furosemide was found to stimulate renin release only in the presence of the macula densa (Fig. 5) . These findings demonstrated for the first time that the macula densa indeed participates in the control of renin release. Consistent with our clinical studies described above, indomethacin was found to inhibit furosemide-induced and macula densa-mediated renin release in our in vitro preparation. Furthermore, we found that PGE2 stimulates renin release in the presence but not the absence of the macula densa (34) . Thus, the renin-stimulating action of f urosemide seems to result from a combination of its direct inhibition of Na-K-2C1 co-transporter at the macula densa and increased renal levels of PGE2 acting within the JGA. In addition to PGs, adenosine seems to play an important role in the macula densa control of renin release, since the adenosine antagonist theopylline abolished the differences in basal renin release between the presence and the absence of the macula densa in our preparation (35) . The roles of PG and adenosine in the macula densa-mediated renin release have also been demonstrated by other investigators employing isolated JGA preparations in which the macula densa (but not the afferent arteriole) is perfused (36) (37) (38) (39) (40) (41) . Finally, we have demonstrated substantial heterogeneity in renin distribution within the kidney, in that renin content and release in the superficial nephrons are about 50 to 100 times as much as those in the juxtamedullary nephrons (42, 43) in rabbits (Fig. 6) . The Kallikrein-Kinin and Prostaglandin Systems The kallikrein-kinin and prostaglandin systems are depressor hormones that are produced within the kidney. They cause natriuresis and diuresis and may play an important role in the control of systemic blood pressure. These systems have been shown to be involved in the anti-hypertensive mechanism of ACEi as well as the diuretic action of furosemide ( Fig. 7) (31, 44) . In 1952, Beraldo (45) reported that kinin is excreted in urine, and its origin was thought to be the blood filtered at the glomerulus. However, we found little change in the urinary excretion rate of kinins even during intrarenal infusion of high doses of bradykinin (46) . These results suggest that filtered kinins are destroyed by the brushborder of the proximal tubule and that kinins excreted in the urine are produced within the kidney. To determine the sites of kallikrein synthesis, Omata et al. (47) employed microdissected nephron segments and found that most of the kininogenase activities are present in the connecting tubules. Subsequent microperfusion studies by Tomita et al. (48) have demonstrated that kinins inhibit tubular transport at the collecting tubules.
The PG system is also important in the control of renal functions and systemic blood pressure under certain conditions. It has been shown that non-steroidal anti-inflammatory drugs (NSAIDs) have little effect in normal subjects, but often aggravate renal dys function and cause hypertension in patients with various renal diseases. Frolich et al. (49) have shown that PGs are produced within the kidney, which is indeed the origin of PGs found in urine. Studies with microdissected nephron segments have demonstrated that PGs are produced mainly in the vasculature including the glomerulus and collecting tubules (50). Takeuchi et al. (51) (52) (53) cloned cDNA of the EP3 receptors, a subtype of the PGE2 receptor, from the rat kidney, and analyzed its intrarenal distribution and signal transduction mechanism. They found that mRNA of the EP3 receptors was expressed in the distal nephron, including the thick ascending limb and cortical collecting ducts, while their subtype EP3A and EP3B receptors were coupled to a decrease in intracellular cAMP and an increase in Cat+, respectively, both of which are known to inhibit tubular transport. Thus, the PG system appears to function at the site or vicinity of its production, controlling water and electrolyte balance.
In patients with impaired renal function, the rate of sodium excretion per nephron increases, as evidenced by an exaggerated fractional sodium excretion. In our study the fractional sodium excretion was found to correlate positively with the rate of urinary PGE2 excretion in patients with chronic glomerulonephritis, suggesting that the renal PG system may participate in the control of excretory functions of residual nephrons (54, 55) . In addition, urinary PGE2 excretion was found to be reduced in patients with essential hypertension, suggesting that renal PG may play a role in the pathophysiology of hypertension (56, 57) . In another study, we further assessed the role of PG in both the BP and renin responses to sodium depletion in essential hypertension (Fig. 8) . We found that sodium-depletion decreases BP in low-renin hypertensive patients, with addition of indomethacin abolishing the hypotensive effect. In contrast, in normal-renin hypertensive patients, sodium depletion increased PRA, which re- turned to the basal level upon addition of indomethacin, whereas BP remained unchanged throughout the study. Thus, PGs seem to play important roles in both renin release and the pathophysiology of low-renin essential hypertension. However, it is not clear how PGs are involved in the salt-sensitivity of blood pressure. It may be that sodium depletion increases the renal level of PGs, which in turn affect glomerular hemodynamics and tubular functions, resulting in reduced BP. It is interesting to note that in salt-sensitive hypertension in humans and animals, renal blood flow does decrease upon salt-loading, which may contribute to salt-retention and the development of hypertension (10, 58) . Such decreases in renal blood flow are associated with increases in glomerular capillary pressure, which are attributed to increased efferent arteriolar resistance. In order to define the role of PGs in the glomerular microcirculation, we developed in vitro preparations in which isolated efferent arterioles are perfused either from their distal end (retrograde perfusion) or from the end of the afferent arterioles through the glomerulus (orthograde perfusion) (59) . Since the efferent arteriolar perfusate passes through the glomerulus only in orthograde perfusion, vasoactive substances released by the glomerulus could modulate vascular reactivities in the downstream efferent arteriole (Fig. 9) . We found that both angiotensin (Ang) II and norepinephrine (NE) caused much weaker constriction of the efferent arteriole in orthograde than in retrograde perfusion, while inhibition of PG synthesis with indomethacin augmented the vasoconstriction only in orthograde perfusion. These results suggest that the glomerulus may control its own capillary pressure (and hence the rate of ultrafiltration) by releasing PGs and thereby adjusting the resistance of the downstream efferent arterioles. It is speculated that sodium depletion may increase glomerular synthesis of PGs, which in turn dilate the efferent arterioles. Such dilation of the efferent arteriole would be strong particularly in lowrenin hypertension, since renin release and hence intrarenal Ang II levels (a predominant regulator of efferent arteriolar resistance) are unresponsive to sodium depletion.
Therapy of Hypertension Associated with Renal Dysfunction
Systemic hypertension is often associated with various renal diseases and is a risk factor for renal failure. It is now clear that management of systemic blood pressure is an important means of treating progressive renal disease (60) (61) (62) (63) . When renal injury occurs and the number of functional nephrons decreases, the remaining nephrons undergo a series of compensatory changes (both functional and structural), including hypertrophy and hyperfiltra- tion. Studies have suggested that such adaptational changes are actually linked to progressive loss of renal function. Brenner et al. (11) have provided evidence that glomerular hypertension may cause glomerular sclerosis, leading to further loss of functional nephrons. These findings suggest that treating not only systemic but also glomerular hypertension is important in conserving renal function. Thus understanding the mechanism of action of various antihypertensive drugs as well as their influences on glomerular hemodynamics is imperative in order to select suitable drugs for the treatment of hypertension with various degrees of renal dysfunction (64) . Clinical studies have proven that ACEi retard the rate of progression of renal function in diabetic nephropathy (60, 61) . Recent studies suggest that they may be beneficial in other renal diseases as well (65) . ACEi block the conversion of Ang I to Ang II, thereby reducing systemic blood pressure. Using isolated microperfused afferent and efferent arterioles, we have shown that the efferent arteriole is more sensitive to Ang II than is the afferent arteriole (15) . Thus, ACEi preferentially dilate the efferent arteriole and hence reduce glomerular capillary pressure. However, the GFR changes much less than would be accounted for by a fall in glomerular capillary pressure, since ACEi increase both renal blood flow and ultrafiltration coefficient. In addition, ACEi inhibit cell proliferation and hypertrophy as well as the accumulation of extracellular matrix. Thus, ACEi are expected to exert renoprotective effects independently of the level of systemic blood pressure.
Calcium antagonists inhibit calcium influx through voltage-sensitive calcium channels, thereby relaxing vascular smooth muscle cells and reducing systemic blood pressure. It has been shown that voltagesensitive calcium channels are critically involved in afferent arteriolar constriction induced by virtually all mechanisms, including the myogenic response and TGF. Indeed we have shown that calcium antagonists dilate isolated microperfused afferent arterioles preconstricted with NE (66) . Such dilation of the afferent arteriole makes glomerular capillary pressure dependent on systemic blood pressure. Thus, glomerular capillary pressure can be reduced or normalized only when systemic blood pressure is well controlled. This may explain the equivocal efficacy of calcium antagonists in conserving kidney function in clinical studies, even though animal studies suggest that they exert a renoprotective effect by inhibiting hypertrophy (67) .
We have conducted a prospective, multicenter clinical trial to examine how low the systemic blood pressure should be controlled to prevent the progression of renal dysfunction in patients with mild to moderate renal dysfunction and to study whether calcium antagonists or ACEi have renoprotective effects (68) . This study was designed by The Research Group of Progressive Renal Lesions, Intractable Disease Division (Kiyoshi Kurokawa, Director), and was supported by the Public Health Bureau, the Ministry of Health and Welfare, Japan. All the patients enrolled in the study (n =104) had a creatinine clearance of equal or greater than 50 mllmin and underwent renal biopsy for histological examination. About of 40% of the patients had IgA nephropathy and the remaining patients had other renal parenchymal diseases. Patients with nephrotic syndrome or diabetes mellitus were excluded. On the basis of ambulatory blood pressure (ABP) levels, the patients were classified as hypotensive, normotensive, and hypertensive according to the criteria defined for each age group by a large epidemiological study. The hypertensive patients were treated with either ACEi or calcium antagonists, and all patients were followed up for an average of 3 yr (Fig. 10 ). As shown in Fig. 11 , we found that the lower the systemic blood pressure, the less was the mean slope of the reciprocal of serum creatinine (lIScr), suggesting that the ABP levels needed to protect renal function were lower than the normal levels as defined at the beginning of the study. In patients treated with calcium antagonists, hypertension was associated with progression of renal dysfunction, whereas both normotension and hypotension were associated with improved renal function (Fig. 12) . These results suggest that the renoprotective effect of calcium antagonist is pressuredependent. In contrast, ACEi had beneficial effects on renal function regardless of the level of systemic blood pressure (Fig. 13) . These results are compatible with the pharmacological actions of calcium antagonists and ACE discussed earlier.
An increase in glomerular plasma flow enhances the rate of glomerular filtration at the single nephron level even without changes in glomerular capillary pressure. In addition, it stimulates the glomerular endothelium to release NO and PGs, which increase Kf and inhibit both cell proliferation and hypertrophy. Thus, decreased glomerular capillary pressure combined with increased glomerular plasma flow is likely to have the most favorable effect on the long-term renal function. In theory, this can be attained by the combined use of an calcium antagonist and an ACEi, which causes dilation of both afferent and efferent arterioles. Indeed, we have recently observed that in 5/6 nephrectomized SHR, treatment with both a calcium antagonist and an ACEi had the most favorable effects on proteinuria, Scr, and histologic findings as compared with monotherapy with either drug alone, although the level of systemic blood pressure was similar in all three groups (69) . However, clarification of whether combined use is superior to either a calcium antagonist or ACEi alone in human nephropathies must await further investigations.
